Abstracts tagged "Abatacept"

Abstract Number: 2910 • 2013 ACR/ARHP Annual Meeting
Differences In Abatacept Use In Rheumatoid Arthritis Patients Across Europe: A Pan-European Database Analysis Of Abatacept In European RA Registries
David Neto¹, Axel Finckh², Florenzo Iannone³, Estíbaliz Loza⁴, Elisabeth Lie⁵, Piet L.C. Van Riel⁶, Merete L. Hetland⁷, Karel Pavelka⁸, Jacques-Eric Gottenberg⁹, Xavier Mariette¹⁰ and Carl Turesson¹¹, ¹University of Geneva, Geneva, Switzerland, ²Rheumatology, Geneva University Hospital, Geneva, Switzerland, ³D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
Background/Purpose: Several European registries have pooled data of patients (pts) who received Abatacept (ABA) for rheumatoid arthritis (RA) to acquire new knowledge about performance of…
Abstract Number: 468 • 2013 ACR/ARHP Annual Meeting
The Differential Role Of T Helper Cells In The Pathogenesis and Responsiveness To Abatacept Therapy In Rheumatoid Arthritis
Shunsuke Fukuyo¹, Shingo Nakayamada², Kunihiro Yamaoka¹, Satoshi Kubo¹, Shigeru Iwata³, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan
Background/Purpose: Abatacept (ABT) works through a different mechanism of action from TNF inhibitors in the treatment of rheumatoid arthritis (RA). ABT decreases T cell responses…
Abstract Number: 2349 • 2013 ACR/ARHP Annual Meeting
Abatacept and Anti-Tumor Necrosis Factor Monoclonal Antibodies: Efficacy and Safety Comparisons
M Schiff¹, Maxime Dougados², Roy Fleischmann³, J Fay⁴ and M Maldonado⁴, ¹University of Colorado, Denver, CO, ²Rheumatology, Hopital Cochin, Descartes University, Paris, France, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A paucity of clinical trial data exists comparing the efficacy and safety of biologic therapies for RA. This study evaluated remission rates and safety…
Abstract Number: 476 • 2013 ACR/ARHP Annual Meeting
Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab
Roy Fleischmann¹, M Schiff², M E Weinblatt³, M Maldonado⁴, E Massarotti⁵ and Y Yazici⁶, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³Brigham & Women's Hospital, Boston, MA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Brigham and Women's Hospital, Boston, MA, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Remission and low disease activity (LDA) are now more achievable goals in RA. Year 1 data from the head-to-head AMPLE (Abatacept vs Adalimumab Comparison…
Abstract Number: 2326 • 2013 ACR/ARHP Annual Meeting
Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
Michael E. Weinblatt¹, Michael H Schiff², Robert Valente³, Désirée M. van der Heijde⁴, Gustavo Citera⁵, Ayanbola Elegbe⁶, Michael A Maldonado⁶ and Roy Fleischmann⁷, ¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Denver, CO, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) is the first 2 year, active comparator study in RA patients utilizing…
Abstract Number: 454 • 2013 ACR/ARHP Annual Meeting
Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept
MC Genovese¹, Clifton O. Bingham III², S Cohen³, Leonard H. Calabrese⁴, JR Curtis⁵, A Block⁶, J Fay⁶, S Kelly⁷, A Luo⁶, D Wong⁶ and R Alten⁸, ¹Stanford University, Palo Alto, CA, ²Johns Hopkins University, Baltimore, MD, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Cleveland Clinic Foundation, Cleveland, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Plainsboro, NJ, ⁸Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Previous small studies have suggested that responses to some immunizations may be attenuated by intravenous abatacept but remain clinically meaningful.1,2 We investigated the magnitude…
Abstract Number: 1342 • 2012 ACR/ARHP Annual Meeting
Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael E. Weinblatt², Michael H. Schiff³, Dinesh Khanna⁴, Daniel Furst⁵ and Michael A. Maldonado⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Rheumatology Division, University of Colorado, Denver, CO, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁶Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid arthritis (RA) is associated with pain, fatigue, disability and functional loss, which can significantly impact a patient's health-related quality of life (HRQoL). Patient-Reported…
Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Masahiro Sekiguchi¹, Kiyoshi Matsui¹, Masayasu Kitano¹, Mitsuo Namiki¹, Koichiro Ohmura², Takao Fujii³, Hideko Nakahara⁴, Keiji Maeda⁴, Hideo Hashimoto⁵, Takanori Kuroiwa⁶, Kenji Miki⁷, Masanori Funauchi⁸, Kazuhiro Hatta⁹, Kenshi Higami¹⁰, Shunzo Namiuchi¹¹, Ichiro Yoshii¹², Teruyuki Nakatani¹³, Takashi Ikawa¹⁴, Takaji Matsutani¹⁵, Kosaku Murakami¹⁶, Satoshi Morita¹⁷, Yutaka Kawahito¹⁸, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology & Clin Immunology, Kyoto University, Kyoto, Japan, ³Dept of Rheum/Clinical Immun, Graduate School of Medicine,, Kyoto University, Kyoto, Japan, ⁴Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁵Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁶Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁸Division of Hematology and Rheumatology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan, ⁹Department of Internal Medicine, Tenri Yorozu Sodansyo Hospital, Nara, ¹⁰Department of Rheumatology, Higami Hospital, Nara, Japan, ¹¹Department of Rheumatology, Saiseikai Nakatsu Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Department of Orthopaedic Surgery, Kishiwada City Hospital, Osaka, Japan, ¹⁴Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁵Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ¹⁶Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁷Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁸Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁹Dept of Rheum & Clinical Immun, Kyoto University, Kyoto, Japan
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…
Abstract Number: 1309 • 2012 ACR/ARHP Annual Meeting
Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Alain G. Cantagrel³, Bernard Combe⁴, René-Marc Flipo⁵, Thierry Schaeverbeke⁶, Eric Houvenagel⁷, Philippe Gaudin⁸, Damien Loeuille⁹, Stephanie Rist¹⁰, Maxime Dougados¹¹, Jean Sibilia¹², Xavier Le Loet¹³, Christian Marcelli¹⁴, Thomas Bardin¹⁵, Isabelle Pane¹⁶, Elodie Perrodeau¹⁷, Gabriel Baron¹⁸ and Xavier Mariette¹⁹, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Rheumatology Department, Lille University Hospital, Lille, France, ⁶Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁷Service de Rhumatologie, St Philibert Hospital, Lomme 59462, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ¹⁰Hospital University Orléans, France, ¹¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ¹²Rheumatology, CHU Hautepierre, Strasbourg, France, ¹³Rheumatology Department, CHU de ROUEN, Rouen, France, ¹⁴Rheumatology Department, Caen University Hospital, ¹⁵Rheumatology, Hôpital Lariboisière, Paris, France, ¹⁶Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁷Epidemiologist, Paris, France, ¹⁸Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ¹⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Little data is available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis treated with abatacept (ABA) in daily…
Abstract Number: 1271 • 2012 ACR/ARHP Annual Meeting
Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results From the Nationwide Danish Danbio Registry
HC Leffers¹, Mikkel Østergaard¹, Bente Glintborg², Niels Steen Krogh³, Ulrik Tarp⁴, Tove Lorenzen⁵, Annette Hansen⁶, Michael Sejer Hansen⁷, Lene Dreyer², Martin S. Jakobsen² and Merete Lund Hetland⁸, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Gildhøj Privathospital, Copenhagen, Denmark, ⁸DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark
Background/Purpose: Abatacept and tocilizumab have been shown to be efficacious for the treatment of rheumatoid arthritis (RA), even in patients refractory to tumor necrosis factor…
Abstract Number: 810 • 2012 ACR/ARHP Annual Meeting
Assessment of Omeract Global Power Doppler Ultrasonography 44-Joint Scoring System and Reduced Joint Scoring Systems in Rheumatoid Arthritis Patients Treated with Abatacept Plus Background Methotrexate
MA D'Agostino¹, R. Wakefield², H. Berner Hammer³, O. Vittecoq⁴, M. Galeazzi⁵, P. Balint⁶, E. Filippucci⁷, I. Moller⁸, A. Iagnocco⁹, E. Naredo¹⁰, Mikkel Ostergaard¹¹, C. Gaillez¹², K. Van Holder¹³, M. Le Bars¹² and OMERACT-US Task Force¹⁴, ¹AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University Hospital, Rouen, France, ⁵University of Siena, Siena, Italy, ⁶National Institute, Budapest, Hungary, ⁷University Politecnica delle Marche, Ancona, Italy, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Severo Ochoa, Madrid, Spain, ¹¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ¹²Bristol-Myers Squibb, Rueil Malmaison, France, ¹³Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁴Paris
Background/Purpose: The first international trial using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) synovitis scoring system1 showed early and significant signs of improvement in…
Abstract Number: 811 • 2012 ACR/ARHP Annual Meeting
The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept-Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate
MA D'Agostino¹, R. Wakefield², H. Berner Hammer³, O. Vittecoq⁴, M. Galeazzi⁵, P. Balint⁶, E. Filippucci⁷, I. Moller⁸, A. Iagnocco⁹, E. Naredo¹⁰, Mikkel Ostergaard¹¹, C. Gaillez¹², K. Van Holder¹³, M. Le Bars¹² and OMERACT Ultrasound Task Force¹⁴, ¹AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University Hospital, Rouen, France, ⁵University of Siena, Siena, Italy, ⁶National Institute, Budapest, Hungary, ⁷University Politecnica delle Marche, Ancona, Italy, ⁸Instituto Poal, Barcelona, Spain, ⁹Sapienza Università di Roma, Roma, Italy, ¹⁰Hospital Severo Ochoa, Madrid, Spain, ¹¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ¹²Bristol-Myers Squibb, Rueil Malmaison, France, ¹³Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ¹⁴Paris
Background/Purpose: An exploratory study using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) scoring system1 in patients (pts) with established RA and inadequate response to…
Abstract Number: 460 • 2012 ACR/ARHP Annual Meeting
Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
H. Nüßlein¹, R. Alten², M. Galeazzi³, H. M. Lorenz⁴, Dimitrios Boumpas⁵, M. T. Nurmohamed⁶, W. Bensen⁷, Gerd Burmester⁸, H.-H. Peter⁹, F. Rainer¹⁰, Karel Pavelka¹¹, M. Chartier¹², C. Poncet¹³, C. Rauch¹⁴ and M. Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University Medical Center Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Sévres, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil Malmaison, France
Background/Purpose: Randomized controlled trials (RCTs) of abatacept (ABA) in patients (pts) with RA have demonstrated sustained, long-term efficacy, high pt retention, and consistent safety.1 Data…
Abstract Number: 462 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
M. C. Genovese¹, C. Pacheco-Tena², A. Covarrubias³, Gustavo Leon⁴, E. Mysler⁵, M. Keiserman⁶, R. Valente⁷, P. Nash⁸, J. A. Simon-Campos⁹, J. Box¹⁰, C. Legerton III¹¹, E. Nasonov¹², P. Durez¹³, I. Delaet¹⁴ and R. Alten¹⁵, ¹Stanford University, Palo Alto, CA, ²Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ³Centro Medico De Las Americas, Merida, Mexico, ⁴Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁵Organización Médica de Investigación, Buenos Aires, Argentina, ⁶Pontificial Catholic University School of Medicine, Porto Alegre, Brazil, ⁷Arthritis Center of Nebraska, Lincoln, NE, ⁸Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁹Centro De Especialidades Médicas/Universidad Marista, Merida, Mexico, ¹⁰Carolina Bone and Joint, Charlotte, NC, ¹¹Low Country Rheumatology, Charleston, SC, ¹²Institute of Rheumatology, Moscow, Russia, ¹³Université Catholique de Louvain, Brussels, Belgium, ¹⁴Bristol-Myers Squibb, Princeton, NJ, ¹⁵Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: The Abatacept (ABA) Comparison of Sub[QU]cutaneous (SC) versus Intravenous (IV) in Inadequate Responders to MethotrexatE (MTX) (ACQUIRE) study showed comparable efficacy and safety of…
Abstract Number: 2449 • 2012 ACR/ARHP Annual Meeting
Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Michael E. Weinblatt¹, Michael H. Schiff², Roy Fleischmann³, Robert Valente⁴, Désirée van der Heijde⁵, Gustavo Citera⁶, Cathy Zhao⁷ and Michael A. Maldonado⁸, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology Division, University of Colorado, Denver, CO, ³Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁴Arthritis Center of Nebraska, Lincoln, NE, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose : The availability of multiple biologic agents to treat rheumatoid arthritis (RA) has created a need for comparative assessment. AMPLE (Abatacept Versus Adalimumab Comparison…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].